16 Mar, 2026
Feel free to reach out to us.
16 Mar, 2026
Cervical cancer treatment depends on disease stage, tumor characteristics, and individual circumstances. The five main approaches are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Early-stage disease may be managed with surgery alone. Locally advanced cancer is treated with concurrent chemoradiation. Advanced or recurrent cases now have systemic options, including immune checkpoint inhibitors and antibody-drug conjugates. A multidisciplinary team of gynecologic oncologists, radiation oncologists, and medical oncologists reviews each case before any recommendation reaches the patient.
Two patients with the same stage may receive different recommendations. Tumor size, lymph node involvement, cell behavior, kidney function, and fertility goals all factor in.
Good to know: Fertility needs to come up at the very first appointment. Some early-stage options preserve the uterus, but that window closes once a hysterectomy is performed.
At many centers, tumor board meetings bring together specialists from different disciplines to review complex cases before presenting a plan to the patient.
Surgery is the primary treatment for most early-stage cervical cancer.
Minor Procedures for Microscopic Tumors: A cone biopsy or LEEP may remove all cancer when it is found only under a microscope. Both take out a cone-shaped section of cervical tissue and leave the uterus intact.
Trachelectomy: removing the cervix, keeping the uterus. For selected patients with small early-stage tumors who want children, radical trachelectomy removes the cervix and surrounding tissue while preserving the uterus. Lymph nodes are assessed at the same time. Eligibility depends on tumor size, type, and node findings.
Quick note: If future pregnancy matters, raise your concerns before treatment planning moves forward.
Radical Hysterectomy: For most Stage IB and IIA cervical cancers, this removes the uterus, cervix, part of the vagina, and pelvic lymph nodes. Radiation may follow if cancer cells are found at surgical edges or in nodes.
Pelvic Exenteration: This procedure is reserved for rare cases of locally recurrent disease confined to the center of the pelvis. This is a major procedure offered only in specific clinical situations.
Radiation destroys cancer cells using high-energy beams. Two types are almost always combined.
External beam radiation therapy (EBRT) is a radiotherapy approach wherein the radiation beams come from a machine outside the body, targeting the pelvis over several weeks.
Brachytherapy is a form of internal radiation therapy. A radioactive source placed inside or next to the cervix delivers a concentrated dose at the tumor site while limiting exposure to the bladder and bowel.
Radiation may serve as the main treatment when surgery is not appropriate, be combined with chemotherapy for locally advanced disease, or follow surgery when clearance is uncertain.
Chemotherapy in cervical cancer is most commonly given alongside radiation, not alone. This combination, concurrent chemoradiation, is the standard for locally advanced disease (Stage IIB through IVA). Chemotherapy sensitizes cancer cells, making radiation more effective.
Platinum-based agents, including cisplatin and carboplatin, are most commonly used. The oncologist selects the regimen based on kidney function and overall health.
For metastatic or recurrent disease, chemotherapy may also serve as systemic treatment, sometimes combined with targeted therapy or immunotherapy.
Quick note: If kidney function is a concern, your oncologist may choose carboplatin over cisplatin. The goal is the most effective treatment your body can safely handle.
For advanced, recurrent, or metastatic cervical cancer, drugs beyond conventional chemotherapy are now part of established care.
Bevacizumab blocks the formation of new blood vessels; tumors need to grow. Used with chemotherapy for certain advanced cases, it limits tumor expansion rather than killing cancer cells directly.
Pembrolizumab is an immune checkpoint inhibitor that blocks PD-L1, a protein some tumors use to hide from immune detection. It is approved for certain patients with advanced or recurrent disease and for high-risk locally advanced cervical cancer alongside chemoradiation.
Bottom line: Eligibility depends on biomarker testing of the tumor tissue, not stage alone.
Tisotumab vedotin, an antibody-drug conjugate, is approved for recurrent or metastatic disease progressing after chemotherapy. Clinical trials continue expanding immunotherapy’s role in cervical cancer.
| Stage | Typical Treatment Approach |
|---|---|
| Stage IA1 | Cone biopsy, LEEP, or simple hysterectomy; trachelectomy if fertility desired |
| Stage IA2 / IB1 | Radical trachelectomy or radical hysterectomy; chemoradiation as alternative |
| Stage IB2 / IB3 / IIA | Radical hysterectomy with lymph node dissection, or concurrent chemoradiation |
| Stage IIB / III / IVA | Concurrent chemoradiation (EBRT plus brachytherapy); pembrolizumab may be added |
| Stage IVB | Systemic therapy (chemotherapy with or without bevacizumab or immunotherapy) |
| Recurrent | Pelvic exenteration (local); systemic therapy (distant); palliative care throughout |
Recurrent cervical cancer is treated differently from the original diagnosis.
Local pelvic recurrences without prior radiation in that area may be treated with chemoradiation. If surgery is feasible, pelvic exenteration may be considered for selected patients.
Distant recurrence affecting lungs, liver, or bones uses systemic therapy as the primary approach. Chemotherapy, bevacizumab, immunotherapy, or combinations may be used depending on prior treatment and current health.
Palliative care manages symptoms, reduces pain, and maintains quality of life alongside active treatment.
The standard surgical treatment, radical hysterectomy, permanently ends the possibility of pregnancy. Trachelectomy preserves the uterus for patients meeting specific criteria: small tumor, favorable lymph node findings, and careful assessment by the gynecologic oncologist.
Good to know: Once a hysterectomy is done, nothing reverses it. Raise the question before a surgical plan is finalized.
Cervical cancer treatment works best with a coordinated, multidisciplinary team reviewing each case carefully. HCG’s approach centers on this principle: specialists across medical, surgical, and radiation oncology collaborating through structured case discussions, guided by the “right treatment, first time” philosophy. With Comprehensive Cancer Centers across India, HCG provides evidence-based oncology expertise closer to home through its Hub and Spoke Model.
If you or someone you care about is facing this diagnosis, a detailed consultation with a gynecologic oncology team that can review every available option is the most useful next step.
- National Cancer Institute (NCI) | Cervical Cancer Treatment | https://www.cancer.gov/types/cervical/treatment
- National Cancer Institute (NCI) | Cervical Cancer Treatment by Stage | https://www.cancer.gov/types/cervical/treatment/by-stage
- American Cancer Society | Treatment Options for Cervical Cancer, by Stage | https://www.cancer.org/cancer/types/cervical-cancer/treating/by-stage.html
- Mayo Clinic | Cervical Cancer Diagnosis and Treatment | https://www.mayoclinic.org/diseases-conditions/cervical-cancer/diagnosis-treatment/drc-20352506
- PubMed Central / NCBI | Cervical Cancer Therapies: Current Challenges and Future Perspectives | https://pmc.ncbi.nlm.nih.gov/articles/PMC9062473/
- Cancer Research Institute | Immunotherapy for Cervical Cancer | https://www.cancerresearch.org/immunotherapy-by-cancer-type/cervical-cancer
